CytomX Tangible Book Value Per Share from 2010 to 2024

CTMX Stock  USD 0.89  0.02  2.30%   
CytomX Therapeutics Tangible Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Tangible Book Value Per Share is likely to outpace its year average in 2024. During the period from 2010 to 2024, CytomX Therapeutics Tangible Book Value Per Share regression line of annual values had r-squared of  0.0003 and arithmetic mean of  0.97. View All Fundamentals
 
Tangible Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
(0.67)
Current Value
(0.63)
Quarterly Volatility
4.04042706
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.1 M or Selling General Administrative of 28.8 M, as well as many indicators such as Price To Sales Ratio of 1.07, Dividend Yield of 0.0299 or Days Sales Outstanding of 11.76. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CytomX Therapeutics Correlation against competitors.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Latest CytomX Therapeutics' Tangible Book Value Per Share Growth Pattern

Below is the plot of the Tangible Book Value Per Share of CytomX Therapeutics over the last few years. It is CytomX Therapeutics' Tangible Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Tangible Book Value Per Share10 Years Trend
Very volatile
   Tangible Book Value Per Share   
       Timeline  

CytomX Tangible Book Value Per Share Regression Statistics

Arithmetic Mean0.97
Geometric Mean1.59
Coefficient Of Variation418.57
Mean Deviation2.41
Median(0.63)
Standard Deviation4.04
Sample Variance16.33
Range16.6793
R-Value0.02
Mean Square Error17.58
R-Squared0.0003
Significance0.95
Slope0.02
Total Sum of Squares228.55

CytomX Tangible Book Value Per Share History

2024 -0.63
2023 -0.67
2022 -1.33
2021 1.36
2020 1.03
2019 1.08
2018 3.08

About CytomX Therapeutics Financial Statements

CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' Tangible Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Tangible Book Value Per Share(0.67)(0.63)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.